Proactive Investors - Run By Investors For Investors

Imugene raises $3M from option plan to advance immunotherapy studies

Imugene is developing an immunotherapy to treat gastric cancer.
Imugene raises $3M from option plan to advance immunotherapy studies
Immuno-oncology is a highly promising field

Imugene (ASX:IMU) has raised circa $3 million as part of an option plan which expired on 31 March 2017, at a price of $0.015 per share.

The new capital places Imugene in a solid position to continue the development of its clinical candidate, HER-Vaxx.

HER-Vaxx is a cancer immunotherapy designed to treat HER-2 positive gastric cancer, a cancer with increased levels of a growth-promoting protein called the HER-2 receptor.

Immuno-oncology is a relatively new but highly promising field that uses the method of activating a patient's immune system against tumour growth.

Imugene’s three prominent existing shareholders, Private Portfolio Managers, Platinum Asset Management and Celtic Capital, have increased their investment in Imugene via their roles as underwriters to the plan.

In January 2016, Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets.

This partnership has the potential to create B Cell peptide vaccines that would replace or augment conventional monoclonal antibodies.

Importantly, Imugene filed four new patent applications with IP Australia in December 2016 related to mimotope B-cell vaccine compositions.

The company’s share price increased circa 78% during the past six months, last trading at $0.016.

View full IMU profile View Profile

Imugene Ltd Timeline

October 19 2016

Related Articles

car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
researcher filling a tray of samples
December 14 2018
The company has two clinical trials underway and is well funded to achieve its immediate ambitions
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use